For over 20 years, Dr. Jessica Tate has been at the forefront of viral vector research, pioneering groundbreaking advancements in the gene therapy industry. With a Ph.D. in molecular genetics from the University at Buffalo, she has leveraged her extensive expertise to facilitate the progression of more than 70 viral vector products, four of which have reached pivotal or commercial stages. As a seasoned leader, Jessica has held key roles in process development, tech transfer, and process characterization, while also spearheading the creation and expansion of new teams and facilities. Her impressive body of work includes several publications and U.S. patents, cementing her reputation as a trailblazer in the field of Viral Vector Technologies.